血栓性素因の世界市場レポート 2024年

血栓性素因市場規模は近年力強く成長しています。2023年の159億7,000万米ドルから2024年には172億3,000万米ドルに、CAGR7.9％で拡大します。歴史的な期間に観察された成長は、意識の高まり、抗凝固療法の広範な研究開発、人口の高齢化、遺伝子研究の進歩、血栓性疾患の顕著な増加など、いくつかの要因によるものです。

血栓性素因市場規模は、今後数年間で力強い成長が見込まれます。2028年の年間平均成長率（CAGR）は7.8％で、233億1,000万米ドルに成長します。予測期間中に予想される成長は、個別化医療の登場、革新的な治療法のイントロダクション、ヘルスケア診療への人工知能の統合、ヘルスケア政策と政策の影響、患者教育とエンパワーメントの高まりなど、さまざまな要因に関連しています。この期間に予想される重要な動向には、技術の進歩、遠隔医療の利用拡大、罹患率の上昇傾向、バイオ医薬品の継続的開発、共同研究イニシアチブの増加が含まれます。

予想される高齢者人口の増加は、今後の血栓性素因市場の拡大を牽引するものと思われます。高齢者人口」とは65歳以上の人口を指し、人口全体に占める割合の増加は人口動態の変化を意味します。血栓性危険因子は高齢者に多く、有害な臨床転帰のリスクを有する高齢者を特定する手段となります。その結果、高齢者人口の増加が血栓性素因医薬品の需要を促進すると予想されます。2022年現在、米国の健康ランキングのデータによると、65歳以上の成人は5,600万人を超え、米国総人口の約16.9％を占める。2030年の予測では、7,310万人以上の高齢者が見込まれており、ベビーブーマー世代の高齢化と重なります。この人口動向は、血栓性素因市場の成長を促進する重要な要因です。

血栓性疾患の有病率の増加は、今後の血栓性素因市場の成長に大きく貢献すると予測されています。血栓性素因性疾患は、診断、治療アプローチ、進行中の調査に影響を与え、血栓性素因市場の展望を形成する上で重要な役割を果たしています。例えば、2023年8月、Nuffield Trustのデータから、英国は深部静脈血栓性素因（DVT）の症例数がデータを提供している8カ国の中で最も多いことが明らかになった。2021年には352例であったが、2022年には退院者10万人あたり377例に増加しました。このような血栓性疾患の有病率の急増は、血栓性素因市場を牽引する重要な要因となっています。

2023年の血栓性素因市場で最大の地域は北米でした。血栓性素因市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 血栓性素因市場の特徴

第3章 血栓性素因市場の動向と戦略

第4章 血栓性素因市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の血栓性素因市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 血栓性素因市場セグメンテーション

• 世界の血栓性素因市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• ファクターVライデン
• プロトロンビン20210
• 抗リン脂質症候群
• その他
• 世界の血栓性素因市場、医薬品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ヘパリン
• ワルファリン
• その他
• 世界の血栓性素因市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• その他
• 世界の血栓性素因市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• ホームケア
• 専門センター
• その他

第7章 血栓性素因市場の地域および国分析

• 世界の血栓性素因市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の血栓性素因市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋の血栓性素因市場

第9章 中国血栓性素因市場

第10章 インドの血栓性素因市場

第11章 日本の血栓性素因市場

第12章 オーストラリアの血栓性素因市場

第13章 インドネシアの血栓性素因市場

第14章 韓国の血栓性素因市場

第15章 西欧の血栓性素因市場

第16章 英国の血栓性素因市場

第17章 ドイツの血栓性素因市場

第18章 フランスの血栓性素因市場

第19章 イタリアの血栓性素因市場

第20章 スペインの血栓性素因市場

第21章 東欧の血栓性素因市場

第22章 ロシアの血栓性素因市場

第23章 北米血栓性素因市場

第24章 米国の血栓性素因市場

第25章 カナダの血栓性素因市場

第26章 南米血栓性素因市場

第27章 ブラジルの血栓性素因市場

第28章 中東の血栓性素因市場

第29章 アフリカの血栓性素因市場

第30章 血栓性素因市場の競合情勢と企業プロファイル

• 血栓性素因市場の競合情勢
• 血栓性素因市場の企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Limited
  • Mylan NV
  • Changzhaou Qianhong Bio-pharma Co. Limited
  • Fresenius Kabi AG

第31章 世界の血栓性素因市場の競合ベンチマーキング

第32章 世界の血栓性素因市場競争ダッシュボード

第33章 血栓性素因市場における主要な合併と買収

第34章 血栓性素因市場の将来展望と可能性分析

第35章 付録

“Thrombophilia Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thrombophilia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thrombophilia? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The thrombophilia market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Factor V Leiden; Prothrombin 20210; Antiphospholipid Syndrome; Other Type
• 2) By Drugs: Heparin; Warfarin; Other Drugs
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
• 4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End Users
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Limited; Mylan N.V.; Changzhaou Qianhong Bio-pharma Co. Limited; Fresenius Kabi AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Thrombophilia denotes a blood condition heightening the likelihood of clot formation within veins and arteries, potentially stemming from arterial or venous clotting or a hereditary (genetic) or acquired predisposition. This condition bears the potential to trigger severe health complications such as heart attacks, strokes, kidney failure, and pulmonary embolisms.

The primary thrombophilia types encompass factor V Leiden, prothrombin 20210, antiphospholipid syndrome, among others. Factor V Leiden involves a mutation in one of the blood-clotting factors. Treatment options include medications such as Heparin, Warfarin, and others, administered through various routes including oral and parenteral. End-users of these treatments span across hospitals, home health agencies, specialty centers, and similar entities.

The thrombophilia market research report is one of a series of new reports from. The Business Research Company that provides thrombophilia market statistics, including thrombophilia industry global market size, regional shares, competitors with a thrombophilia market share, detailed thrombophilia market segments, market trends and opportunities, and any further data you may need to thrive in the thrombophilia industry. This thrombophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thrombophilia market size has grown strongly in recent years. It will grow from $15.97 billion in 2023 to $17.23 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth observed during the historic period can be credited to several factors, including heightened awareness, extensive research and development in anticoagulant therapies, the aging population demographic, advancements in genetic research, and a notable rise in the occurrence of thrombotic disorders.

The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $23.31 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period is linked to various factors, including the advent of personalized medicine, the introduction of innovative therapies, the integration of artificial intelligence into healthcare practices, the impact of healthcare policies and regulations, and an upsurge in patient education and empowerment. Significant trends expected in this period encompass advancements in technology, the expanded utilization of telemedicine, an upward trend in incidence rates, ongoing developments in biopharmaceuticals, and an increase in collaborative research initiatives.

The anticipated growth in the elderly population is poised to drive the expansion of the thrombophilia market in the future. The term 'elderly population' refers to individuals aged 65 and older, and their increasing proportion within the overall population signifies a demographic shift. Thrombophilic risk factors are prevalent in the elderly, providing a means to identify those at risk for adverse clinical outcomes. Consequently, the rise in the elderly population is expected to fuel demand for thrombophilia drugs. As of 2022, data from America's Health Rankings indicates that more than 56 million adults aged 65 and older constitute approximately 16.9% of the total US population. Projections for 2030 estimate over 73.1 million older individuals, coinciding with the aging of the baby boomer generation. This demographic trend is a key driver propelling the growth of the thrombophilia market.

The increasing prevalence of thrombophilic conditions is anticipated to contribute significantly to the growth of the thrombophilia market in the years ahead. Thrombophilic diseases, characterized by an elevated predisposition to blood clot formation (thrombosis), play a crucial role in shaping the thrombophilia market landscape, influencing diagnosis, treatment approaches, and ongoing research. For example, in August 2023, data from the Nuffield Trust revealed that the UK had the highest number of cases of Deep Vein Thrombosis (DVT) among eight nations providing data. In 2021, there were 352 cases, increasing to 377 for every 100,000 hospital discharges in 2022. This surge in the prevalence of thrombophilic conditions serves as a key factor driving the thrombophilia market.

Technological advancements are a predominant trend in the thrombophilia market, with major companies actively engaged in developing innovative technologies to maintain and enhance their market positions. In 2021, the University of Oslo, a Norway-based public research university, introduced a groundbreaking technology known as super albumin, potentially revolutionizing the creation of long-acting drugs for individuals with hemophilia, a condition affecting the blood's clotting ability. The university's research group employed an advanced biomedical technique to produce coagulation factors with significantly extended half-lives. Super albumin, a protein variant developed through this research, can be combined with protein-based drugs to prolong their bloodstream half-life, showcasing the potential impact of cutting-edge biomedical approaches in the thrombophilia market.

Major companies in the thrombophilia market are strategically pursuing partnerships to advance the development of biosynthetic heparin. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. For example, in January 2022, Optimvia, LLC, a US-based biotechnology company, announced a partnership with Ginkgo Bioworks with the aim of enhancing the efficiency of biosynthetic heparin synthesis. Optimvia plans to utilize Ginkgo's cell and enzyme engineering systems, along with its fermentation manufacturing capabilities, to expedite the improvement of its biosynthetic heparin production method. The collaboration aims to create commercially viable, cost-effective, and safe biosynthetic heparin, potentially reducing the global dependence on heparin sourced from livestock. Ginkgo Bioworks, a US-based company specializing in cell programming, provides a platform to support this innovative partnership in the thrombophilia market.

In March 2022, Pfizer Inc., a prominent US-based pharmaceutical company, successfully completed the acquisition of Arena Pharmaceuticals for a substantial sum of $6.7 billion. As a result of this acquisition, Arena Pharmaceuticals has now become a subsidiary of Pfizer. This strategic move is anticipated to foster innovations aimed at enhancing the lives of individuals grappling with immuno-inflammatory disorders. Arena Pharmaceuticals, Inc., the acquired entity, is based in the United States and is dedicated to developing treatments for thromboembolic disorders affecting the arterial blood vessels. The acquisition reflects Pfizer's commitment to expanding its portfolio and capabilities in the field of pharmaceuticals, particularly in addressing disorders related to the immune and inflammatory systems.

Major companies operating in the thrombophilia market report are Pfizer Inc., F. Hoffmann-La Roche Limited, Mylan N.V., Changzhaou Qianhong Bio-pharma Co. Limited, Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. Limited, Hikma Pharmaceuticals PLC., Novartis AG, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Yino Pharma Limited, Aspen Insurance Holdings Limited, Sanofi SA, Eisai Co. Limited, Boehringer Ingelheim GmbH, Siemens, LabCorp, Instrumentation Laboratory SpA, Johnson & Johnson, Laurus Lab, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, GlaxoSmithKline plc, CSL Behring .

North America was the largest region in the thrombophilia market in 2023. The regions covered in the thrombophilia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the thrombophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombophilia market consists of sales of rivaroxaban, apixaban, and thrombolytics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Thrombophilia Market Characteristics

3. Thrombophilia Market Trends And Strategies

4. Thrombophilia Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Thrombophilia Market Size and Growth

• 5.1. Global Thrombophilia Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Thrombophilia Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Thrombophilia Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Thrombophilia Market Segmentation

• 6.1. Global Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Factor V Leiden
• Prothrombin 20210
• Antiphospholipid Syndrome
• Other Type
• 6.2. Global Thrombophilia Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Heparin
• Warfarin
• Other Drugs
• 6.3. Global Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Route Of Administration
• 6.4. Global Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Homecare
• Speciality Centres
• Other End Users

7. Thrombophilia Market Regional And Country Analysis

• 7.1. Global Thrombophilia Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Thrombophilia Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Thrombophilia Market

• 8.1. Asia-Pacific Thrombophilia Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Thrombophilia Market

• 9.1. China Thrombophilia Market Overview
• 9.2. China Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Thrombophilia Market

• 10.1. India Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Thrombophilia Market

• 11.1. Japan Thrombophilia Market Overview
• 11.2. Japan Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Thrombophilia Market

• 12.1. Australia Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Thrombophilia Market

• 13.1. Indonesia Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Thrombophilia Market

• 14.1. South Korea Thrombophilia Market Overview
• 14.2. South Korea Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Thrombophilia Market

• 15.1. Western Europe Thrombophilia Market Overview
• 15.2. Western Europe Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Thrombophilia Market

• 16.1. UK Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Thrombophilia Market

• 17.1. Germany Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Thrombophilia Market

• 18.1. France Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Thrombophilia Market

• 19.1. Italy Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Thrombophilia Market

• 20.1. Spain Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Thrombophilia Market

• 21.1. Eastern Europe Thrombophilia Market Overview
• 21.2. Eastern Europe Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Thrombophilia Market

• 22.1. Russia Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Thrombophilia Market

• 23.1. North America Thrombophilia Market Overview
• 23.2. North America Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Thrombophilia Market

• 24.1. USA Thrombophilia Market Overview
• 24.2. USA Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Thrombophilia Market

• 25.1. Canada Thrombophilia Market Overview
• 25.2. Canada Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Thrombophilia Market

• 26.1. South America Thrombophilia Market Overview
• 26.2. South America Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Thrombophilia Market

• 27.1. Brazil Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Thrombophilia Market

• 28.1. Middle East Thrombophilia Market Overview
• 28.2. Middle East Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Thrombophilia Market

• 29.1. Africa Thrombophilia Market Overview
• 29.2. Africa Thrombophilia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Thrombophilia Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Thrombophilia Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Thrombophilia Market Competitive Landscape And Company Profiles

• 30.1. Thrombophilia Market Competitive Landscape
• 30.2. Thrombophilia Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Limited
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Mylan N.V.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Changzhaou Qianhong Bio-pharma Co. Limited
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Fresenius Kabi AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Thrombophilia Market Competitive Benchmarking

32. Global Thrombophilia Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Thrombophilia Market

34. Thrombophilia Market Future Outlook and Potential Analysis

• 34.1 Thrombophilia Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Thrombophilia Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Thrombophilia Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer